Table 12.

Treatment-related adverse events in study 3

		Cohort 1		Cohort 2		Cohort 3
	Placebo n = 9	300 mg b.i.d. n = 9	600 mg b.i.d. n = 8	600 mg b.i.d. n = 9	900 mg b.i.d. n = 8	900 mg b.i.d. n = 9	1200 mg q.d. n = 9
Number of subjects with >1 Adverse event*	9	9	6	8	8	8	8
Abdominal pain	2	1	1	2	1	0	2
Asthenia	1	0	0	4	1	6	4
Headache	3	2	1	3	5	3	2
Postural hypotension	0	0	0	0	0	5	6
Dry mouth	0	0	2	0	1	2	3
Flatulence	1	2	0	1	0	1	1
Nausea	1	2	2	4	3	4	2
Hyperlipidaemia	1	0	0	0	0	0	2
Dizziness	2	2	2	6	7	3	3
Somnolence	0	0	0	4	6	0	0
Cough increased	1	1	0	1	2	0	0
Epistaxis	0	0	0	2	4	0	1
Pharyngitis	1	3	2	0	0	0	0
Rhinitis	0	1	3	2	4	2	3
Rash	2	0	1	0	0	0	1
Abnormal vision	0	0	1	2	3	3	0
Conjunctivitis†	0	0	0	0	5	4	5
Eye pain	1	0	0	1	2	1	1

^*Table shows adverse events that were reported by more than one subject in any treatment group.

^†The investigator term for all the cases of conjunctivitis was bloodshot eyes.